JCCG 活動情報 －論文投稿 2018 年―
（主）
：主論文

神経芽腫委員会（主）Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa
A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H,Tajiri T, Nakagawara A. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol.
23:965. 2018. PMID:29700636
Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. Jpn J Clin Oncol. 48:214.
2018. PMID:29378002

腎腫瘍委員会（主）Koshinaga T, Takimoto T, Oue T, Okita H, Tanaka Y, Nozaki M, Tsuchiya, Kunihiko,Inoue E, Haruta
M, Kaneko Y, Fukuzawa M. Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS2): A report from the Japan Children's Cancer Group (JCCG). Pediatr Blood Cancer. 65:e27056. 2018.
PMID:29630767

肝腫瘍委員会
Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, Hiyama E, Czauderna P, Roebuck
DJ, Tiao GM. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood
revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 48:536. 2018.
PMID:29427028（主）Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna
P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, VealGJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate forProtection from Cisplatin-Induced Hearing Loss. N Engl J Med. 378:2376. 2018. PMID:29924955

リンパ腫委員会
Koga Y, Baba S, Fukano R, Nakamura K, Soejima T, Maeda N, Sunami S, Ueyama J, Mitsui T, Mori T,Osumi T, Sekimizu M, Ohki K, Tanaka F, Kamei M, Fujita N, Mori T, Saito AM, Kada A, Kobayashi R.
The Effect of Interim FDG-PET-guided Response-Adapted Therapy in Pediatric Patients with Hodgkin's
Lymphoma (HL-14) : Protocol for a Phase II Study. Acta Med Okayama. 72:437. 2018. PMID:30140095
Sekimizu M, Fujimoto J, Takimoto T, Tsurusawa M, Horibe K, Sunami S. Phase II Clinical Trial for Newly
DiagnosedChildrenandAdolescentswithLocalized

Lymphoblastic

Lymphoma(JapaneseLeukemia/Lymphoma Study Group Trial LLB-NHL03) : Study Protocol for Nationwide Multicenter Trial.
Acta Med Okayama. 72:427. 2018. PMID:30140093
Sekimizu M, Hashimoto H, Mori T, Kobayashi R, Horibe K, Tsurusawa M. Efficacy and safety ofadministering pediatric treatment to adolescent patients with mature B-cell non-Hodgkin lymphoma within
the Japanese Pediatric Leukemia/Lymphoma Study Group clinical trial. Pediatr Blood Cancer. 65:e27068.
2018. PMID:29637700
Fukano R, Sunami S, Sekimizu M, Takimoto T, Mori T, Mitsui T, Mori T, Saito AM, Watanabe T, Ohshima
K, Fujimoto J, Nakazawa A, Kiyokawa N, Kobayashi R, Horibe K, Tsurusawa M. Clinical Features andPrognosis According to Immunophenotypic Subtypes Including the Early T-Cell Precursor Subtype of TLymphoblastic Lymphoma in the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03
Study. J Pediatr Hematol Oncol. 40:e34. 2018. PMID:28538509

AML 委員会
Matsuo H, Iijima-Yamashita Y, Yamada M, Deguchi T, Kiyokawa N, Shimada A, Tawa A, Tomizawa D,Taga T, Kinoshita A, Adachi S, Horibe K. Monitoring of fusion gene transcripts to predict relapse inpediatric acute myeloid leukemia. Pediatr Int. 60:41. 2018. PMID:29067751
Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, Tawa A, Takahashi H,Tomizawa D, Taga T, Kinoshita A, Adachi S, Horibe K. Multiplex fusion gene testing in pediatric acute
myeloid leukemia. Pediatr Int. 60:47. 2018. PMID:29105243
Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T,Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y,Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, SuehiroY, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S,

Adachi S, Kiyoi H. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid
leukemia. Int J Hematol. 107:201. 2018. PMID:29027108
Shimada A, Iijima-Yamashita Y, Tawa A, Tomizawa D, Yamada M, Norio S, Watanabe T, Taga T, Iwamoto
S, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Saito AM,Kiyokawa N, Horibe K, Hara Y, Oki K, Hayashi Y, Tanaka S, Adachi S. Risk-stratified therapy for children
with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. Int J Hematol.
107:586. 2018. PMID:29330746
Yamato G, Shiba N, Yoshida K, Hara Y, Shiraishi Y, Ohki K, Okubo J, Park MJ, Sotomatsu M, Arakawa H,Kiyokawa N, Tomizawa D, Adachi S, Taga T, Horibe K, Miyano S, Ogawa S, Hayashi Y. RUNX1 mutations
in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis.
Blood. 131:2266. 2018. PMID:29540347
Tomizawa D, Tanaka S, Hasegawa D, Iwamoto S, Hiramatsu H, Kiyokawa N, Miyachi H, Horibe K, Saito
AM, Taga T, Adachi S. Evaluation of high-dose cytarabine in induction therapy for children with de novo
acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless
Phase II-III Randomized Trial (JPLSG AML-12). Jpn J Clin Oncol. 48:587. 2018. PMID:29889285
Noort S, Zimmermann M, Reinhardt D, Cuccuini W, Pigazzi M, Smith J, Ries RE, Alonzo TA, Hirsch B,Tomizawa D, Locatelli F, Gruber TA, Raimondi S, Sonneveld E, Cheuk DK, Dworzak M, Stary J,Abrahamsson J, Arad-Cohen N, Czogala M, De Moerloose B, Hasle H, Meshinchi S, van den HeuvelEibrink M, Zwaan CM. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML:a retrospective study by the I-BFM Study Group. Blood. 132:1584. 2018. PMID:30150206
Matsuo H, Yoshida K, Fukumura K, Nakatani K, Noguchi Y, Takasaki S, Noura M, Shiozawa Y, ShiraishiY, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Shiba N, Yamato G, Handa H, Ono Y,Hiramoto N, Ishikawa T, Usuki K, Ishiyama K, Miyawaki S, Itonaga H, Miyazaki Y, Kawamura M,Yamaguchi H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Hayashi Y, Mano H, Miyano S, Kamikubo Y,Ogawa S, Adachi S. Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. Blood Adv.
2:2879. 2018. PMID:30381403

CML 委員会
Kurosawa H, Tanizawa A, Muramatsu H, Tono C, Watanabe A, Shima H, Ito M, Yuza Y, Hamamoto K,Hotta N, Okada M, Saito AM, Manabe A, Mizutani S, Adachi S, Horibe K, Ishii E, Shimada H. Sequential
use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid

leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer.
65:e27368. 2018. PMID:30084127

HLH/LCH 委員会
Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, Goto H, Kosaka Y, Tsunematsu Y,Imashuku S, Japan LCH Study Group (JLSG) . Intensification of induction therapy and prolongation ofmaintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with singlesystem multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol
Study. Int J Hematol. 108:192. 2018. PMID:29594922

ALL 委員会
Koh K, Kato M, Saito AM, Kada A, Kawasaki H, Okamoto Y, Imamura T, Horibe K, Manabe A. Phase II/III
study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia:
protocol for a nationwide multicenter trial in Japan. Jpn J Clin Oncol. 48:684, 2018. PMID:29860341
児玉祐一，嶋田博之. フィラデルフィア染色体陽性急性リンパ性白血病（Ph+ALL）：チロシンキナーゼ阻害薬（イマチニブやダサチニブなど）併用化学療法（保険承認）. 小児内科. 50:1532. 2018.

CML 委員会・長期フォローアップ委員会共同
Shimada H, Kada A, Shima H, Tono C, Yuza Y, Kurosawa H, Watanabe A, Ito M, Uryu H, Kamibeppu K,Kiyokawa N, Adachi S, Saito M A, Tanizawa A. Rationale and design of a prospectice, multicentre, stoptyrosine kinase inhibitor trial of pesdiatric patients with chronic myeloid leukemia with sustained complete
moleculat response (STKI-14). Hiroshima J Med Sci. 67:7. 2018.